prpf38b Antibody
Description
Introduction to PRPF38B Antibody
PRPF38B (Pre-mRNA Processing Factor 38B) is a component of the U4/U6.U5 tri-snRNP complex essential for spliceosome maturation during mRNA processing . Antibodies targeting PRPF38B enable researchers to study its expression patterns (nuclear, cytoplasmic, or membranous) and correlate these with clinical outcomes in diseases such as breast cancer . Two commercially available antibodies are widely used:
Applications in Research
PRPF38B antibodies are validated for multiple techniques:
Prognostic Significance in Breast Cancer
A study of 1,650 invasive breast carcinomas revealed distinct prognostic implications based on PRPF38B localization :
Survival Analysis (5-Year Follow-Up):
| Cohort | Hazard Ratio (95% CI) | Significance |
|---|---|---|
| ER-negative + Nuclear | 0.64 (0.48–0.86) | p = 0.002 |
| HER2+ + Membranous (No Trastuzumab) | 1.65 (1.07–2.53) | p = 0.02 |
| HER2+ + Membranous (Trastuzumab) | 0.21 (0.08–0.52) | p = 0.00018 |
Clinicopathological Correlations
Membranous PRPF38B expression correlates with aggressive tumor features :
| Feature | Membranous vs. Non-Membranous | p-Value |
|---|---|---|
| High tumor grade (G3) | 76.7% vs. 45.8% | <0.0001 |
| HER2 overexpression | 56.8% vs. 7.8% | <0.0001 |
| High mitotic index (>18) | 69.9% vs. 40.2% | <0.0001 |
Clinical Implications
PRPF38B antibody-based assays help stratify breast cancer patients:
Product Specs
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
What is PRPF38B and why is it important in cancer research?
PRPF38B (PRP38 Pre-mRNA Processing Factor 38 Domain Containing B) is a protein traditionally associated with pre-mRNA splicing and commonly perceived as being located within the nucleus of cells. Research has revealed its significant role as a potential cancer biomarker, particularly in breast cancer. The protein demonstrates variable subcellular localization patterns with distinct clinical implications - nuclear expression is associated with better prognosis while membranous expression correlates with aggressive disease features . This makes PRPF38B antibodies valuable tools for defining disease status and providing prognostic insights in breast cancer management.
What cellular distribution patterns does PRPF38B exhibit in normal versus cancerous tissues?
-
64% of invasive breast cancer cases show no PRPF38B staining
-
25.9% display nuclear staining
-
10.7% exhibit membranous staining
This altered distribution pattern, particularly the membranous localization, represents a potentially important cancer-specific modification that could be exploited for diagnostic and prognostic purposes.
What applications are PRPF38B antibodies validated for?
Based on commercial antibody specifications and published research, PRPF38B antibodies have been validated for several applications:
| Application | Validated Use | Typical Dilutions |
|---|---|---|
| Western Blotting (WB) | Yes | 1:500-1:2000 |
| Immunohistochemistry (IHC) | Yes | 1:200-1:500 |
| ELISA | Yes | 1:5000-20000 |
| Immunofluorescence | Limited data | Consult manufacturer |
Researchers should note that optimal dilutions may vary between antibody sources and specific experimental conditions .
How should researchers optimize immunohistochemistry protocols for detecting different cellular localizations of PRPF38B?
When optimizing IHC for PRPF38B detection, researchers should consider:
-
Antigen retrieval methods - critical for exposing epitopes without disrupting tissue architecture
-
Antibody concentration - titrate using 1:200-1:500 as starting range
-
Incubation conditions - optimize temperature and duration
-
Detection systems - particularly important when evaluating membrane versus nuclear staining
-
Evaluation criteria - establish clear scoring systems for different subcellular localizations
-
Controls - include normal breast tissue (showing nuclear staining) as reference standard
Special attention should be given to distinguishing true membranous staining from artifacts, as membranous localization has significant prognostic implications in breast cancer .
What is the prognostic significance of different PRPF38B localization patterns in breast cancer?
The subcellular localization of PRPF38B has significant prognostic implications:
This differential prognostic significance based on subcellular localization makes accurate detection and interpretation of PRPF38B staining patterns crucial for clinical applications.
How does PRPF38B expression correlate with established clinicopathological features in breast cancer?
Membranous PRPF38B expression shows significant associations with aggressive breast cancer features:
Nuclear PRPF38B expression shows opposite associations, correlating with less aggressive features including ER-positive, PR-positive, and HER2-negative status .
How can researchers validate the specificity of PRPF38B antibodies for their specific applications?
A comprehensive validation approach for PRPF38B antibodies should include:
-
Positive controls - test on cell lines with known PRPF38B expression (HEK-293, K-562, NIH/3T3)
-
Western blot analysis - confirm appropriate molecular weight (~60 kDa)
-
Blocking peptide competition - demonstrate specific binding inhibition
-
Multiple antibody comparison - test multiple antibodies targeting different epitopes
-
Genetic manipulation - validate using PRPF38B knockdown/knockout models
-
Cross-reactivity assessment - test on tissues known to lack PRPF38B expression
Researchers should also verify species reactivity, as different commercial antibodies show varying cross-reactivity with human, mouse, rat, and other species .
What methodological approaches can help resolve contradictory findings about PRPF38B's role in different cancer subtypes?
To address potential contradictions in research findings:
-
Standardize detection methods - use consistent antibodies, protocols, and scoring systems
-
Employ multiple detection techniques - combine IHC with Western blotting or other methods
-
Perform subtype-specific analyses - stratify results based on molecular subtypes with adequate sample sizes
-
Account for heterogeneity - use tissue microarrays with multiple cores per tumor
-
Correlate with functional studies - validate findings with in vitro experiments
-
Consider temporal dynamics - investigate expression changes during disease progression
-
Perform multi-institutional validation - collaborate to increase sample size and diversity
This systematic approach can help clarify PRPF38B's role across different cancer subtypes and reconcile apparently contradictory findings.
How should experiments be designed to investigate the mechanism behind PRPF38B translocation from nucleus to membrane?
To investigate PRPF38B translocation mechanisms:
-
Conduct comparative proteomics of nuclear versus membranous PRPF38B complexes
-
Perform site-directed mutagenesis of potential trafficking signals or post-translational modification sites
-
Use live-cell imaging with fluorescently tagged PRPF38B to monitor trafficking in real-time
-
Test effects of pathway inhibitors targeting various trafficking mechanisms
-
Examine correlation with activation of specific oncogenic signaling pathways
-
Compare translocation dynamics in different breast cancer molecular subtypes
-
Investigate potential splicing variants that might affect subcellular localization
Understanding this translocation mechanism could provide insights into breast cancer pathogenesis and potentially identify new therapeutic targets.
What considerations are important when selecting PRPF38B antibodies for specific research applications?
When selecting PRPF38B antibodies, researchers should consider:
For studies of subcellular localization, select antibodies validated specifically for distinguishing between nuclear and membranous staining patterns.
